On April 26-28, the 4th Xiangya Congress on Health Management were grandly held on the banks of the Xiangjiang River. This conference adheres to the theme of "Collaborative Innovation to Meet Challenges, Open Integration to Enjoy the Future", and closely follows the hot topics of practice for a three-day academic exchange, fully showcasing the exploration and application of new theories, technologies, and practices in today's health management.

At the “Tumor Precise Early Screening Forum” held on the afternoon of April 27th, Professor Jiang Sunfang, Director of the Health Management Center of Zhongshan Hospital affiliated with Fudan University, presented a wonderful report on the application of the innovative biomarker miRNA7 liver cancer testing in health management. Director Jiang systematically introduced the new progress of liquid biopsy molecular markers and the application of miRNA7 as a novel blood molecular marker in early screening of hepatocellular carcinoma, which received enthusiastic feedback and widespread praise from experts and scholars present.

Plasma microRNAs (miRNAs), as a novel tumor biomarker, can stably exist in peripheral blood and have been widely studied and proven to be involved in the disease progression of liver cancer. From the perspective of clinical research value and application, Director Jiang introduced the establishment of a liver cancer diagnostic model using seven miRNA markers in plasma, as well as the clinical application of miRNA7™ testing kits. Research has shown that a liver cancer diagnostic model based on plasma seven miRNAs has a detection rate of 86.1% for very early liver cancer, which is 30% higher than the traditional marker AFP, demonstrating great potential for accurate diagnosis of very early liver cancer. The sensitivity and specificity of miRNA7™ for AFP negative liver cancer were 77.7% and 84.5%, respectively, which were significantly better than the detection of traditional biomarkers, once again confirming the solid detection performance of miRNA7™.

She further introduced that miRNA7™ is the first Class III liver cancer molecular detection product approved by the National Medical Products Administration (NMPA) in China, and has been included in multiple authoritative guidelines and consensus such as the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition). It has won the second prize of the National Science and Technology Progress Award in 2020, marking the clinical application of miRNA7™liver cancer detection kits has been highly recognized by the nation.

Finally, Director Jiang pointed out that the advantage of miRNA7™ in the full process management of liver cancer is significant, with an average advance of 11.5 months indicating the risk of hepatocellular carcinoma compared to imaging examinations, the detection rate of very early liver cancer is 30% higher than traditional methods such as AFP, which can effectively detect AFP negative hepatocellular carcinoma. Under the premise of effectiveness of miRNA7™ confirmed by previous data, initiated by the China Health Promotion Foundation in collaboration with the Health Management Branch of the Chinese Medical Association, and led by the Health Management Center of Zhongshan Hospital affiliated with Fudan University, the second batch of research projects on multicenter application of miRNA7 ™ focusing on early liver cancer screening for physical examination population has been launched, and health management centers from 23 top tier hospitals nationwide have jointly participated in the evaluation of miRNA7™, which will help to accumulate more excellent performance data on the value of early liver cancer screening in continuous monitoring of high-risk populations for liver cancer and physical examination populations.

We firmly believe that with the application and promotion of miRNA7™ in the field of health management will continue to improve the early diagnosis rate and 5-year survival rate of liver cancer in China, making a significant contribution to achieving early diagnosis of liver cancer, and steadily promoting the implementation of the Healthy China Action.